AtheroGenics Starts Pivotal Diabetes Trial
Posted on: Friday, 24 August 2007, 12:13 CDT
AtheroGenics has started enrollment of the first patients in a Phase III clinical trial of its oral anti-diabetic agent with anti-inflammatory and antioxidant properties.
The double-blind, placebo controlled study will be conducted at sites in the US, South Africa, Eastern Europe and India. The trial is designed to randomly assign approximately 1,200 patients with confirmed type II diabetes mellitus to one of three doses of AGI-1067 (75, 150, and 300mg) or placebo for 25 weeks.
All patients enrolled in the trial will be on one or no anti-diabetic medication. The key objective of the trial is to compare the effects three doses of AGI-1067 versus placebo on glycemic endpoints. AtheroGenics is planning to conduct an interim analysis in mid-2008, and the study is expected to conclude before the end of 2008.
Source: Datamonitor
Related Articles
- Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
- Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
- S*BIO Becomes Singapore's First Biotech Company To Initiate Clinical Trial of Novel Anti-Cancer Drug
- MedImmune Expands Anti-Interferon-Alpha Program By Initiating Phase 1 Trial in Patients With Psoriasis
- Cobalis Reports All Patient Diaries in Phase III Clinical Trials for OTC Anti-Allergy Product Candidate Are Completed
- Kemia Announces Completion of Phase I Trials for Oral Anti-Inflammatory Drug; KC706, a P38 MAP Kinase Inhibitor, Targets Inflammatory Conditions Including Arthritis, Psoriasis, and Cardiovascular Disease
- Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients With Cardiovascular Disease
- IDM Closes Enrollment to Its EP-2101 Therapeutic Vaccine Trial in Patients With Non-Small Cell Lung Cancer
- Pain Therapeutics Reports Oxytrex(TM) Results From a Large Trial in Patients With Moderate-to-Severe Osteoarthritic Pain
- Data and Safety Monitoring Board Recommends Discontinuation of Canvaxin(TM) Phase 3 Clinical Trial for Patients With Stage III Melanoma
 |
 |
User Comments (0)
RSS Feeds